Thermoresponsive Hydrogel Microparticles for Sustained Ocular Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current ocular hypotensive medications for glaucoma, such as brimonidine tartrate, require frequent dosing and have not been adapted into controlled-release formulations, leading to low patient compliance and inefficient drug delivery due to high absorption barriers in the eye.
Innovation Solution
A thermoresponsive hydrogel containing agent-loaded polymer microparticles is topically delivered to the ocular surface, forming a sustained release structure in the lower fornix, allowing for at least five days of sustained drug delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If frequent dosing of ocular hypotensive medications is used, then intraocular pressure reduction is achieved, but patient compliance deteriorates
Solution Approach 1:
The patent applies preliminary action by pre-loading polymer microparticles with glaucoma medication during manufacturing, creating a controlled-release reservoir that automatically dispenses drug over time without requiring patient intervention. This transforms the dosing burden from frequent manual administration to a single preparatory action, directly resolving the compliance issue while maintaining IOP reduction effectiveness
Solution Approach 2:
The patent implements continuity of useful action through the controlled-release polymer microparticle system that maintains therapeutic drug levels in the eye over extended periods (days to months). The microparticles continuously release medication through degradation and diffusion, eliminating the need for frequent dosing interruptions and ensuring sustained IOP control, thereby improving patient compliance
2Quantity of substance
If high concentrations of drug are used in eye drops, then absorption barriers in the eye are overcome, but the frequency of administration increases
Solution Approach 1:
The patent applies preliminary action by pre-loading polymer microparticles with therapeutic concentrations of glaucoma medication during manufacturing. The microparticles serve as a reservoir that releases drug continuously over time, allowing the use of high initial drug concentrations without requiring frequent re-administration. This resolves the contradiction by separating the loading phase (high concentration) from the release phase (sustained, lower concentration over time)
3Quantity of substance
If conventional eye drop administration is used, then drug delivery to the eye is achieved, but absorption barriers reduce bioavailability
Solution Approach 1:
The patent introduces polymer microparticles as an intermediary carrier system between the administered drug and the eye's absorption barriers. These microparticles protect the drug from degradation, control its release rate, and facilitate penetration through the blood-aqueous barrier and other ocular absorption barriers. This intermediary approach significantly improves bioavailability while maintaining effective drug delivery
Solution Approach 2:
The patent applies parameter changes by modifying the physical and chemical parameters of drug delivery through polymer microparticle encapsulation. The microparticles control drug release through parameters such as polymer degradation rate, pore size, surface area, and cross-linking density. These parameter modifications enable sustained release and improved bioavailability, resolving the contradiction between drug delivery and absorption barrier penetration
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system provides a non-invasive, self-administered method for sustained drug release, improving compliance and increasing bioavailability by forming a gelled structure that maintains therapeutic levels for an extended period, potentially up to 30 days, without the need for clinical intervention.
Implementation Method 1
topically delivering to the ocular surface a liquid thermoresponsive hydrogel... permitting the liquid hydrogel to form in situ a gelled, sustained release structure
Data Source
AI summary
A method for sustained delivery of an agent to an ocular organ in a subject, comprising topically delivering to the ocular surface a liquid thermoresponsive hydrogel comprising agent-loaded polymer microparticles, wherein the agent is sustainably released for a period of at least five days.